U.S. markets open in 3 hours 3 minutes
  • S&P Futures

    3,308.25
    -25.50 (-0.76%)
     
  • Dow Futures

    27,173.00
    -235.00 (-0.86%)
     
  • Nasdaq Futures

    11,238.00
    -99.75 (-0.88%)
     
  • Russell 2000 Futures

    1,493.50
    -13.50 (-0.90%)
     
  • Crude Oil

    38.87
    -0.42 (-1.07%)
     
  • Gold

    1,889.10
    -14.10 (-0.74%)
     
  • Silver

    23.83
    -0.62 (-2.54%)
     
  • EUR/USD

    1.1715
    -0.0030 (-0.26%)
     
  • 10-Yr Bond

    0.6450
    0.0000 (0.00%)
     
  • Vix

    26.76
    +0.57 (+2.18%)
     
  • GBP/USD

    1.2838
    -0.0022 (-0.17%)
     
  • USD/JPY

    105.6710
    +0.0160 (+0.02%)
     
  • BTC-USD

    10,723.70
    -120.51 (-1.11%)
     
  • CMC Crypto 200

    220.68
    -8.99 (-3.92%)
     
  • FTSE 100

    5,877.71
    -19.79 (-0.34%)
     
  • Nikkei 225

    23,185.12
    -353.98 (-1.50%)
     

Crinetics Pharmaceuticals to Participate in September Investor Conferences

Crinetics Pharmaceuticals, Inc.

SAN DIEGO, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (Nasdaq: CRNX), today announced that management will participate in the following conferences in the month of September and invites investors to participate by webcast. Please see additional details below:

Baird Global Healthcare Conference

 

Date:

 

Wednesday, September 9th 2020

 

 

 

 

Time:

 

12:50 pm Eastern Time

 

 

 

 

Presenter:

 

Scott Struthers, Founder & CEO

 

 

 

 

 

 

 

 

 

 

H.C. Wainwright: 22nd Annual Global Investment Conference

 

 

 

 

Date:

 

Monday, September 14th 2020

 

 

 

 

Time:

 

10:30 am Eastern Time

 

 

 

 

Presenter:

 

Scott Struthers, Founder & CEO

 

 

 

 

 

 

 

 

 

 

Cantor Fitzgerald Global Healthcare Conference

 

 

 

 

Date:

 

Tuesday, September 15th 2020

 

 

 

 

Time:

 

2:00 pm Eastern Time

 

 

 

 

Presenter:

 

Scott Struthers, Founder & CEO

 

 

 

Webcast Links:
Links to the webcasts along with a replay of the webcasts will be accessible on the Events & Presentations page in the Investors section on the Company’s website at www.crinetics.com.  

About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company’s lead product candidate, paltusotine (formerly CRN00808), is an oral selective nonpeptide somatostatin receptor type 2 biased agonist undergoing two Phase 2 clinical trials for the treatment of acromegaly, an orphan disease affecting more than 25,000 people in the United States. Crinetics plans to advance paltusotine into a Phase 3 trial in acromegaly and a Phase 2 trial for the treatment of carcinoid syndrome associated with NETs in 2021. The company is also developing an oral nonpeptide somatostatin receptor type 5 (sst5) agonist for hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease, congenital adrenal hyperplasia and other diseases of excess ACTH. All of the company’s drug candidates are new chemical entities resulting from in-house drug discovery efforts and are wholly owned by the company. For more information, please visit www.crinetics.com.

 

 

 

 

 

 

 

 

 

 

 

Contacts:

 

 

 

 

 

 

 

 

 

Media:

Marc Wilson

 

 

 

 

 

 

 

 

 

Aline Sherwood

Chief Financial Officer

 

 

 

 

 

 

 

 

 

Scienta Communications

IR@crinetics.com 

 

 

 

 

 

 

 

 

 

asherwood@scientapr.com

(858) 450-6464

 

 

 

 

 

 

 

 

 

(312) 238-8957